Schroder Investment Management Group Lowers Position in Insmed, Inc. $INSM

Schroder Investment Management Group trimmed its position in shares of Insmed, Inc. (NASDAQ:INSM) by 31.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 87,615 shares of the biopharmaceutical company’s stock after selling 39,880 shares during the quarter. Schroder Investment Management Group’s holdings in Insmed were worth $8,818,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its stake in shares of Insmed by 24.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 186 shares during the period. ORG Partners LLC boosted its stake in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 196 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in shares of Insmed by 5.2% during the second quarter. Coldstream Capital Management Inc. now owns 4,975 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 244 shares in the last quarter. Hilltop National Bank acquired a new position in Insmed in the 2nd quarter valued at $28,000. Finally, Hsbc Holdings PLC lifted its position in Insmed by 1.5% during the first quarter. Hsbc Holdings PLC now owns 21,423 shares of the biopharmaceutical company’s stock worth $1,613,000 after buying an additional 315 shares during the period.

Insmed Trading Down 0.8%

NASDAQ:INSM opened at $205.04 on Friday. The stock has a fifty day simple moving average of $179.16 and a 200 day simple moving average of $133.54. The firm has a market capitalization of $43.73 billion, a price-to-earnings ratio of -33.12 and a beta of 1.01. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same period last year, the firm earned ($1.27) EPS. The company’s revenue was up 52.4% compared to the same quarter last year. Sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on INSM shares. UBS Group boosted their target price on Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Royal Bank Of Canada increased their price target on Insmed from $139.00 to $215.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Mizuho upped their target price on shares of Insmed from $196.00 to $256.00 and gave the company an “outperform” rating in a research note on Monday. Evercore ISI restated an “outperform” rating and set a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. Finally, Bank of America lifted their target price on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Twenty analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $187.89.

Insiders Place Their Bets

In other Insmed news, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $195.90, for a total value of $14,692,500.00. Following the completion of the sale, the director owned 54,677 shares in the company, valued at approximately $10,711,224.30. This trade represents a 57.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the completion of the sale, the insider directly owned 36,461 shares in the company, valued at approximately $7,073,434. The trade was a 45.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 233,650 shares of company stock valued at $41,063,785 in the last three months. Company insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.